BIOMEA FUSION INC (BMEA)
US09077A1060 - Common Stock
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical...
Noteworthy Wednesday Option Activity: UPS, AMGN, BMEA
Commit To Buy Biomea Fusion At $7.50, Earn 21.8% Annualized Using Options
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage...
BMEA Stock Earnings: Biomea Fusion Misses EPS for Q4 2023
BMEA stock results show that Biomea Fusion missed analyst estimates for earnings per share the fourth quarter of 2023.
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes The first...
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
In 2023, reported Phase 2 data (COVALENT-111) in type 2 diabetes patients supporting the disease-modifying potential of BMF-219 to address a root cause of...
Biomea Fusion Breaks Above 200-Day Moving Average - Bullish for BMEA
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
Bullish speculators could have their opportunity to blow up the bears with these short-squeeze stocks to buy.
Noteworthy Wednesday Option Activity: BMEA, MRNA, EVA
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
Three Clinical Data Sets from the Dose Escalation Phase of COVALENT-111 to be Presented at the 17th Annual ATTD Conference Highlighting BMF-219’s Novel...
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage...
Biomea Fusion Breaks Above 200-Day Moving Average - Bullish for BMEA
Feeling Shut Out? 3 Sizzling Stocks and the Pull-Back Prices to Watch For
Although FOMO can burn, investors will want to be careful with these stock prices to watch as a little patience can go a long way.
3 Speculative Stocks That Could Make Your February Unforgettable
Gambling isn’t for everyone. However, if you’re dead set on speculative stocks, these ideas could shift the odds in your favor.
3 Long-Term Stocks to Buy on the Dip: February 2024
Although these ideas might not be the most exciting in the market, their predictability makes them excellent long-term stocks to buy.
3 Long-Term Stocks to Buy on the Dip: February 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips As someone who has dabbled with high-stakes assets like cryptocurrencies or opt...
Noteworthy Thursday Option Activity: BMEA, WMS, MET
Biomea Fusion Breaks Above 200-Day Moving Average - Bullish for BMEA
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
Expansion portion of Phase II COVALENT-111 study readout in 216 patients with type 2 diabetes expected in 2024.Open label portion of Phase II COVALENT-112...
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes...
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company...
First Week of February 2024 Options Trading For Biomea Fusion (BMEA)